Neurobiology of Aging
Volume 30, Issue 8 , Pages 1205-1216 , August 2009

Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease

  • Jue He

      Affiliations

    • Laboratory of Neuropharmacology, Wenzhou Medical College, Wenzhou, PR China
    • Neuropsychiatry Research Unit, Department of Psychiatry, College of Medicine, University of Saskatchewan, 103 Wiggins Road, Saskatoon, SK S7N 5E4, Canada
    • These authors contributed equally to this work.
    • ,
  • Huanmin Luo

      Affiliations

    • Neuropharmacological Research Lab, College of Pharmacy, Jinan University, 601 Huangpu Road West, Guangzhou 510632, PR China
    • These authors contributed equally to this work.
    • ,
  • Bin Yan

      Affiliations

    • Neuropsychiatry Research Unit, Department of Psychiatry, College of Medicine, University of Saskatchewan, 103 Wiggins Road, Saskatoon, SK S7N 5E4, Canada
    • These authors contributed equally to this work.
    • ,
  • Yingxin Yu

      Affiliations

    • Neuropsychiatry Research Unit, Department of Psychiatry, College of Medicine, University of Saskatchewan, 103 Wiggins Road, Saskatoon, SK S7N 5E4, Canada
    • ,
  • Haitao Wang

      Affiliations

    • Neuropsychiatry Research Unit, Department of Psychiatry, College of Medicine, University of Saskatchewan, 103 Wiggins Road, Saskatoon, SK S7N 5E4, Canada
    • ,
  • Zelan Wei

      Affiliations

    • Neuropsychiatry Research Unit, Department of Psychiatry, College of Medicine, University of Saskatchewan, 103 Wiggins Road, Saskatoon, SK S7N 5E4, Canada
    • ,
  • Yanbo Zhang

      Affiliations

    • Neuropsychiatry Research Unit, Department of Psychiatry, College of Medicine, University of Saskatchewan, 103 Wiggins Road, Saskatoon, SK S7N 5E4, Canada
    • ,
  • Haiyun Xu

      Affiliations

    • Department of Anatomy, School of Medicine, Southern Illinois University Carbondale, 1135 Lincoln Drive, Carbondale, IL 62901, USA
    • ,
  • Adrien Tempier

      Affiliations

    • Neuropsychiatry Research Unit, Department of Psychiatry, College of Medicine, University of Saskatchewan, 103 Wiggins Road, Saskatoon, SK S7N 5E4, Canada
    • ,
  • Xiaokun Li

      Affiliations

    • Laboratory of Neuropharmacology, Wenzhou Medical College, Wenzhou, PR China
    • Corresponding Author InformationCorresponding author.
    • ,
  • Xin-Min Li

      Affiliations

    • Laboratory of Neuropharmacology, Wenzhou Medical College, Wenzhou, PR China
    • Neuropsychiatry Research Unit, Department of Psychiatry, College of Medicine, University of Saskatchewan, 103 Wiggins Road, Saskatoon, SK S7N 5E4, Canada
    • Department of Psychiatry, Faculty of Medicine, University of Manitoba, 727 McDermot Avenue, Winnipeg, MB R3E 3P5, Canada
    • Corresponding Author InformationCorresponding author at: Department of Psychiatry, Faculty of Medicine, University of Manitoba, 727 McDermot Avenue, Winnipeg, MB R3E 3P5, Canada. Tel.: +1 204 789 3616; fax: +1 204 789 3929.

Received 10 May 2007 ,Revised 11 October 2007 ,Accepted 2 November 2007.

References 

  1. Apelt J, Bigl M, Wunderlich P, Schliebs R. Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. Int. J. Dev. Neurosci. 2004;22:475–484
  2. Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 2001;891:42–53
  3. Asai M, Hattori C, Iwata N, Saido TC, Sasagawa N, Szabo B, et al. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J. Neurochem. 2006;96:533–540
  4. Bai O, Wei Z, Lu W, Bowen R, Keegan D, Li XM. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J. Neurosci. Res. 2002;69:278–283
  5. Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res. 2004;1010:81–86
  6. Caballero J, Hitchcock M, Scharre D, Beversdorf D, Nahata MC. Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: A retrospective study. Clin. Ther. 2006;28:1695–1700
  7. Cantillon M, De La Puente AM, Palmer BW. Psychosis in Alzheimer's disease. Semin. Clin. Neuropsychiatry. 1998;3:34–40
  8. Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 1999;2:271–276
  9. Clementi ME, Pezzotti M, Orsini F, Sampaolese B, Mezzogori D, Grassi C, et al. Alzheimer's amyloid beta-peptide (1–42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: an intriguing role for methionine 35. Biochem. Biophys. Res. Commun. 2006;342:206–213
  10. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710–713
  11. Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am. J. Pathol. 2004;164:719–725
  12. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523–527
  13. Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, et al. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol. Aging. 2001;22:377–385
  14. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356
  15. He J, Xu H, Yang Y, Zhang X, Li XM. Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of bcl-2 decrease in rats. Brain Res. 2004;1018:186–192
  16. He J, Xu H, Yang Y, Zhang X, Li XM. Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats. Behav. Brain Res. 2005;160:178–187
  17. He J, Xu H, Yang Y, Rajakumar D, Li X, Li XM. The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of bcl-XL/Bax ratio in the posterior cingulate cortex in rats. Behav. Brain Res. 2006;168:236–242
  18. He J, Yang Y, Yu Y, Li X, Li XM. The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats. Behav. Brain Res. 2006;172:39–45
  19. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 1998;4:97–100
  20. Howard S, Bottino C, Brooke S, Cheng E, Giffard RG, Sapolsky R. Neuroprotective effects of bcl-2 overexpression in hippocampal cultures: interactions with pathways of oxidative damage. J. Neurochem. 2002;83:914–923
  21. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99–102
  22. Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Potter LS, et al. Quetiapine improves psychotic symptoms and cognition in parkinson's disease. Mov. Disord. 2004;19:29–35
  23. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, et al. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science. 1993;262:1274–1277
  24. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for bcl-2 regulation of apoptosis. Science. 1997;275:1132–1136
  25. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell. 2005;120:701–713
  26. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc. Natl. Acad. Sci. U.S.A. 2004;101:3632–3637
  27. Luo C, Xu H, Li XM. Post-stress changes in BDNF and bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine.. Brain Res. 2004;1025:194–202
  28. Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, et al. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 2001;158:1345–1354
  29. Mohmmad Abdul H, Sultana R, Keller JN, St Clair DK, Markesbery WR, Butterfield DA. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid β-peptide (1–42), H2O2 and kainic acid: implications for Alzheimer's disease. J. Neurochem. 2006;96:1322–1335
  30. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods. 1984;11:47–60
  31. Puolivali J, Wang J, Heikkinen T, Heikkila M, Tapiola T, van Groen T, et al. Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol. Dis. 2002;9:339–347
  32. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci. 2001;26:137–149
  33. Qing H, Xu H, Wei Z, Gibson K, Li XM. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur. J. Neurosci. 2003;17:1563–1570
  34. Scharre DW, Chang SI. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis. Assoc. Disord. 2002;16:128–130
  35. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N. Engl. J. Med. 2006;355:1525–1538
  36. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 1999;399:483–487
  37. Storey E, Cappai R. The amyloid precursor protein of Alzheimer's disease and the Abeta peptide. Neuropathol. Appl. Neurobiol. 1999;25:81–97
  38. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen. Psychiatry. 2000;57:968–976
  39. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U.S.A. 1997;94:13287–13292
  40. Suh YH, Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev. 2002;54:469–525
  41. Tong Y, Zhou W, Fung V, Christensen MA, Qing H, Sun X, et al. Oxidative stress potentiates BACE1 gene expression and Abeta generation. J. Neural. Transm. 2005;112:455–469
  42. Van Gassen G, Annaert W. Amyloid, presenilins, and Alzheimer's disease. Neuroscientist. 2003;9:117–126
  43. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, et al. Does cognitive function improve with quetiapine in comparison to haloperidol?. Schizophr. Res. 2002;53:239–248
  44. Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J. Clin. Psychiatry. 2003;64:524–531
  45. Wang H, Xu H, Dyck LE, Li XM. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25–35)-induced oxidative stress and the ensuing apoptosis. J. Neurosci. Res. 2005;81:572–580
  46. Wei Z, Bai O, Richardson JS, Mousseau DD, Li XM. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J. Neurosci. Res. 2003;73:364–368
  47. Wei Z, Mousseau DD, Richardson JS, Dyck LE, Li XM. Atypical antipsychotics attenuate neurotoxicity of beta-amyloid (25–35) by modulating bax and bcl-X(l/s) expression and localization. J. Neurosci. Res. 2003;74:942–947
  48. Wilquet V, De Strooper B. Amyloid-beta precursor protein processing in neurodegeneration. Curr. Opin. Neurobiol. 2004;14:582–588
  49. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am. J. Psychiatry. 1989;146:577–587
  50. Yamada K, Noda Y, Hasegawa T, Komori Y, Nikai T, Sugihara H, et al. The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice. J. Pharmacol. Exp. Ther. 1996;276:460–466
  51. Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 2003;9:3–4
  52. Zhang L, Zhao B, Yew DT, Kusiak JW, Roth GS. Processing of Alzheimer's amyloid precursor protein during H2O2-induced apoptosis in human neuronal cells. Biochem. Biophys. Res. Commun. 1997;235:845–848

PII: S0197-4580(07)00421-6

doi: 10.1016/j.neurobiolaging.2007.11.001

Neurobiology of Aging
Volume 30, Issue 8 , Pages 1205-1216 , August 2009

Article Tools

* Image Usage & Resolution